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A B S T R A C T
Neutrophils ingest Mycobacteria tuberculosis (Mtb) in the lungs of infected individuals. During
phagocytosis they use myeloperoxidase (MPO) to catalyze production of hypochlorous acid (HOCl), their
most potent antimicrobial agent. Isoniazid (INH), the foremost antibiotic in the treatment of tuberculosis,
is oxidized by MPO. It rapidly reduced compound I of MPO [k = (1.22  0.05)  106 M1 s1] but reacted less
favorably with compound II [(9.8  0.6)  102 M1 s1]. Oxidation of INH by MPO and hydrogen peroxide was
unaffected by chloride, the physiological substrate for compound I, and the enzyme was partially converted
to compound III. This indicates that INH is oxidized outside the classical peroxidation cycle. In combination
with superoxide dismutase (SOD), MPO oxidized INH without exogenous hydrogen peroxide. SOD must
favor reduction of oxygen by the INH radical to give superoxide and ultimately hydrogen peroxide. In both
oxidation systems, an adduct with methionine was formed and it was a major product with MPO and SOD.
We show that it is a conjugate of an acyldiimide with amines. INH substantially inhibited HOCl production
by MPO and neutrophils below pharmacological concentrations. The reversible inhibition is explained by
diversion of MPO to its ferrous and compound III forms during oxidation of INH. MPO, along with SOD
released by Mtb, will oxidize INH at sites of infection and their interactions are likely to limit the efficacy of
the drug, promote adverse drug reactions via formation of protein adducts, and impair a major bacterial
killing mechanism of neutrophils.
 2012 Elsevier Inc. All rights reserved.
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Isonicotinic acid hydrazide, or isoniazid (INH), remains an
important drug in the fight against tuberculosis 60 years after its
discovery [1,2]. Resistance of Mycobacterium tuberculosis (Mtb) to
INH, however, is an increasing clinical problem in the management
of this disease worldwide [3]. Given that 30% of the world’s
population is infected with Mtb and 10 million new cases occur
annually, it is critically important to fully understand the
molecular and cellular basis of the action of INH. INH is a pro-
drug that undergoes oxidation in Mtb by a catalase-peroxidase,
KatG [4]. Mutations in KatG that make Mtb resistant to INH blunt
superoxide-dependent oxidation of INH but have little impact on
peroxide-dependent oxidation [5]. These findings suggest that
KatG uses superoxide to oxidize INH within Mtb.
Recently it was shown that neutrophils play a dominant role in
phagocytosis of Mtb in the lungs of infected individuals [6]. This
finding has important implications for the efficacy of INH because* Corresponding author. Tel.: +64 3 364 0590.
E-mail address: louisa.forbes@otago.ac.nz (L.V. Forbes).
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http://dx.doi.org/10.1016/j.bcp.2012.07.020neutrophils contain an abundance of myeloperoxidase (MPO),
which oxidizes INH in a similar fashion to KatG [7,8]. The normal
function of MPO is to promote oxidative killing of bacteria trapped
within phagosomes of neutrophils. This heme enzyme uses
hydrogen peroxide and superoxide to oxidize chloride to hypo-
chlorous acid (HOCl) [9]. The interplay between MPO and INH is of
interest because it may limit the ability of the drug and/or
neutrophils to kill Mtb. For example, oxidation of INH by MPO may
deplete its local concentrations as well as inhibit the production of
HOCl. Oxidation of INH by MPO may also contribute to its
idiosyncratic effects [7,10]. Mtb releases large amounts of SOD
[11,12] and at sites of infection this enzyme is also likely to affect
interactions between MPO, INH and superoxide. An additional
bonus is that an understanding of the mechanism of oxidation of
INH by MPO could provide new insights into how it may be
oxidized by KatG within Mtb.
MPO undergoes enzymatic cycling via its redox intermediates
compounds I and II [13]. When hydrogen peroxide reacts with the
ferric native enzyme, it produces highly reactive compound I,
which has a two-electron reduction potential of 1.16 V [14]. This
enables it to oxidize chloride, bromide and thiocyanate and cycle
back to its native form. Compound I also undergoes one-electron
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radical. Compound II is then reduced back to the native enzyme
and forms another substrate radical. Physiological substrates
include urate, ascorbate, tyrosine and superoxide [13,15]. The
single-electron reduction potential of compound I is 1.36 V
compared to 0.97 V for compound II [16] making the reduction
of compound II the rate determining step in enzyme turnover.
These reduction potentials are higher than the corresponding
values for other peroxidases and give MPO a more diverse
substrate preference. An additional intermediate, compound III
or oxymyeloperoxidase, is generated by reaction of the ferric
enzyme with superoxide, or via one-electron reduction of the
native enzyme to its ferrous state with subsequent binding of
oxygen [13,17,18]. Compound III is less reactive than the other
redox intermediates of MPO but is reduced by ascorbate,
superoxide and serotonin [19–21].
Pharmacological doses of INH cause peak plasma and intra-
pulmonary concentrations of approximately 30 mM [22–24].
Hence, it is conceivable that INH and MPO will interact in vivo.
Previously, activated neutrophils were found to metabolize INH to
a product that exhibited in vitro cytotoxicity raising concerns for
idiosyncratic drug reactions [7,25]. To date, it remains unclear how
effective INH is as a substrate for MPO compared to physiological
substrates and whether it affects the ability of neutrophils to
produce HOCl. Therefore, we have addressed these shortcomings
to fully appreciate how the interactions of INH and MPO influence
both the pharmacology of this important drug and its impact on a
major arm of innate immunity.
2. Materials and methods
2.1. Materials
Human MPO was purchased from Planta Natural Products
(Austria). Its concentration per heme was determined by measur-
ing its absorbance at 430 nm (e430 = 89,000 M1 cm1) [26] and its
purity index, A430/A280 was at least 0.82. Hydrogen peroxide (H2O2,
30% solution) was supplied by LabServ, or from Sigma–Aldrich
(Austria). It was diluted fresh each day and its concentration
determined by measuring its absorbance at 240 nm
(e240 = 43.6 l M1 cm1) [27]. INH, isonicotinic acid, isonicotina-
mide, methionine and lysine compounds, taurine, diethylenetria-
mine penta-acetic acid, tetramethylbenzidine, phorbyl myristate
acetate, superoxide dismutase (from bovine erythrocytes), catalase
(from bovine liver), and Extra-avidin alkaline phosphatase were all
from Sigma–Aldrich (USA). 4-Aminobenzoic acid hydrazide
(ABAH) was from Fluka Chemicals (Germany). For isolation of
neutrophils, Ficoll-Paque (GE Healthcare, Sweden) and dextran
from Leuconostoc mesenteroides (ave. mol. wt. 150,000, Sigma–
Aldrich) were used. The immobilized MPO assay used the following
antibodies: mouse monoclonal antibody to human MPO from
Abcam (UK), goat anti-rabbit biotinylated antibody from Dako
(Denmark) and rabbit polyclonal anti-human MPO (produced in-
house). Reagent Amplex Ultra-Red was from Invitrogen (USA), p-
nitrophenyl phosphate disodium salt was from Strem Chemicals
(USA), and 96-wells flat bottom high binding polystyrene plates
were from Costar (USA). All buffer salts were analytical grade and
solvents were chromatography grade.
2.2. Transient state experiments
The stopped-flow apparatus (model SX-18MV) equipped for
both conventional and sequential stopped-flow measurements
was from Applied Photophysics (UK). For a total of 100 mL/shot
into the optical observation cell with 1 cm light path, the fastest
time for mixing two solutions and recording the first data pointwas of the order of 1.2 ms. All measurements were performed at
25 8C. Due to the inherent instability of MPO compound I, the
sequential stopped-flow (multi-mixing) technique was used for
determination of rates of the reaction of compound I with INH.
Typically, MPO (4 mM) was premixed with H2O2 (40 mM) in the
aging loop for 40 ms in 100 mM phosphate buffer, pH 7.0.
Compound I was then allowed to react with varying concentrations
of INH. Formation of compound II was followed at 456 nm. At least
three determinations were performed for each INH concentration.
The mean of the pseudo-first-order rate constants, kobs, was used in
the calculation of the second-order rate constants obtained from
the slope of a plot of kobs against INH concentrations.
Reactivity of compound II was investigated by starting with
preformed compound II which subsequently reacted with INH
causing an exponential decrease in absorbance at 456 nm. In a
typical experiment, MPO (4 mM) was premixed with a 10-fold
concentration of H2O2 and equimolar homovanillic acid (that
reduces compound I but cannot donate electrons to compound II)
in 100 mM phosphate buffer, pH 7.0. After a delay time of 40 s,
compound II was allowed to react with varying concentrations of
INH in the same buffer.
2.3. HPLC and MS analysis of INH oxidation products
A reverse phase gradient separation was carried out at room
temperature on a Waters Alliance 2690 high pressure liquid
chromatography (HPLC) system using a Phenomenex Gemini-NX
3 mm C18 column (150 mm  2 mm). Solvent A was 20 mM
ammonium acetate buffer (pH 6.9) and solvent B was 100%
methanol. Standards or reaction samples (50 mL) were injected
using an autosampler. After an initial 5 min of 0% B, there were
consecutive linear gradients of 0–40% B over 10 min, 40–75% B
over 1 min with 75% B maintained for another minute, followed by
a return to 0% B over 1 min, then 0% B for a further 7 min. A flow
rate of 200 mL/min was used throughout the 25 min run.
Monitoring the absorbance at 262 nm with an online Waters
996 photodiode array detector allowed detection of INH and its
derivatives. Quantitation by peak area was done using standard
curves for INH, isonicotinic acid and isonicotinamide which were
linear from 0 to 200 mM. Chromeleon software, version 6.80
(Dionex, USA), was used to test eluted peak purity using two
parameters; the peak assymetry measurement standard of
European Pharmcopeia (EP), and the peak purity index (PPI). EP
values between 1.2 and 5.0 are considered to be of acceptable
purity for quantification, and a low percentage relative standard
deviation of the PPI (RSD PPI) indicates low deviation from a
theoretically pure peak.
Identification of eluted isoniazid oxidation products was
confirmed by mass spectrometry (MS). Electrospray ionization
MS analysis was performed using a Thermo LCQ Deca Ion Trap (San
Jose, CA) coupled to a Thermo Surveyor HPLC (LCMS) using
identical gradient conditions as above, with the column held at
25 8C. For the first 4 min, negative ionization was performed for
identification of isonicotinic acid. After 4 min, the mode was
switched to positive ionization. The electrospray was held at 5 kV,
nitrogen (the sheath gas), was set at 38 (arbitrary units)
throughout the run and the capillary temperature was 280 8C.
The fragmentation of isoniazid adducts was performed by MSn
experiments with collision energy at 28–35%, and product ions
monitored from 50 to 300 m/z.
2.4. Spectrophotometric analysis of heme changes in MPO
Visible absorbance spectra were recorded on an Agilent 7500
diode array spectrophotometer operated at room temperature.
Spectra between 190 and 1100 nm (1 nm intervals) were recorded
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readings taken over 1 s. Experiments were performed a minimum
of three times. Prior to analysis of reactions between MPO and INH,
spectra were blanked against INH and, where appropriate, against
catalase. Reactions were typically carried out in a final volume of
500 mL in a quartz cuvette with 1 cm light path, with reagents
added in minimal volume (usually 1–5% final) and mixed within
5 s. Recorded spectra were corrected to overlay the baselines at
800 nm.
2.5. Activity assays for MPO
2.5.1. Taurine chloramine assay in neutrophils and an isolated MPO–
H2O2 system
The chlorination activity of MPO was determined by measuring
the production of HOCl which was trapped as taurine chloramine.
For the MPO–H2O2 system, reaction mixtures contained 20 nM
MPO, 5 mM taurine, and various concentrations of INH in
phosphate buffered saline (PBS; 10 mM sodium/potassium phos-
phate in 137 mM NaCl and 2.7 mM KCl, pH 7.4). Reactions were
carried out at room temperature (21 8C), started by adding 50 mM
H2O2 and stopped after 4–8 min by adding 20 mg/mL catalase. The
reaction time was chosen so that no more than 50% of the H2O2was
converted to HOCl. The trapping of HOCl as taurine chloramine was
assayed using the iodide-catalyzed oxidation of 3,30,5,50-tetra-
methylbenzidine (TMB) [28]. For cell experiments, human
neutrophils were prepared by dextran sedimentation followed
by Ficoll-Paque centrifugation and hypotonic lysis of contaminat-
ing erythrocytes from freshly drawn heparinized-blood of healthy
volunteers [29]. Neutrophils (2  106/mL) were stimulated with
100 ng/mL phorbol 12-myristate 13-acetate (PMA) in Hanks
balanced salt solution (PBS with 0.5 mM magnesium chloride,
1 mM calcium chloride and 5.5 mM glucose), also containing 5 mM
taurine and various concentrations of INH. Reactions were
performed at 37 8C and stopped after 20 min by adding 20 mg/
mL catalase and placing tubes in melting ice. Cells were pelleted by
centrifugation (10,000  g, 3 min) and the accumulated taurine
chloramine was measured in the supernatant as described above.
Single function exponential curves were fitted to the dose–
response data using non-linear regression (SigmaPlot, Jandel
Scientific, USA).
2.5.2. Peroxidation assay
The oxidation of TMB in the absence of halides was used to
determine the peroxidase activity of MPO. This was used as a
measure of residual activity of the enzyme following prior reaction
with inhibitor. Initially, MPO (150 nM) was incubated with 50 mM
INH or ABAH and reactions started by adding 50 mM H2O2. After
30 min reaction mixtures were then diluted 200-fold into 200 mM
acetate buffer, pH 5.4, containing 10% (v/v) dimethylformamide
and a fresh solution of TMB and H2O2 added to give final
concentrations of 2 mM and 200 mM respectively. The absorbance
of oxidized TMB (650 nm) was measured after 10 min. Reactions
were carried out at room temperature and absorbances measured
in a Wallac Victor3 platereader (Perkin Elmer, Singapore).
2.5.3. Activity and protein quantitation of immobilized MPO
To measure irreversible inhibition, the activity of MPO after
incubation with inhibitor was measured as a proportion of its
protein concentration using an enzyme linked immunosorbant
assay (ELISA) [30]. Initially, MPO (150 nM) was incubated for
15 min with either INH (1 mM) or ABAH (1 mM) plus concentra-
tions of H2O2 that ranged from 0 to 100 mM. Reaction mixtures
were then diluted 200-fold for the ELISA. Briefly, plates were
coated with a mouse monoclonal antibody to human MPO which
captured MPO from samples applied in the assay buffer (PBS with1% BSA and 0.025% Tween-20). After washing, the peroxidase
activity was measured first, by adding Amplex Ultra-Red (50 mM),
in 50 mM phosphate buffer, pH 7.4, containing 20 mM H2O2 and
50 mM sodium bromide. Production of the fluorescent Amplex
Ultra-Red oxidation product was measured using lex 544 nm and
lem 590 nm. The plate was washed and then subjected to
quantification of the captured MPO protein. For this a primary
polyclonal rabbit anti-human MPO antibody was followed by a
goat anti-rabbit biotinylated secondary antibody, followed by
Extra-avidin alkaline phosphatase. Finally, the absorbance of the
yellow chromophore from the applied substrate p-nitrophenyl
phosphate disodium salt was measured at 405 nm. Both the
activity and protein measurements were determined using
standard curves from 0 to 680 pM of purified MPO.
3. Results
3.1. Reduction of MPO compounds I and II by INH
To establish how effective INH is as a substrate for compounds I
and II of MPO, we measured the rate constants for these reactions
using stopped-flow spectrophotometry. Measurements of the MPO
transient-state kinetics were made by sequential-mixing stopped-
flow experiments. Compound I of MPO was rapidly converted to
compound II by INH as indicated by a shift of the Soret band from
430 nm to 456 nm with isosbestic points at 433, 494, 574 and
660 nm (Fig. 1A). Additionally, a small maximum appeared at
around 630 nm. The monophasic time traces at 456 nm were fitted
to a single-exponential function (Fig. 1B). The apparent bimolecu-
lar rate constant of the reaction between INH and compound I of
(1.22  0.05)  106 M1 s1 (pH 7.0, 25 8C) was obtained from the
slope of the pseudo-first order rate constants plotted against INH
concentration (Fig. 1C).
By contrast, compound II of MPO reacted very slowly with INH.
Direct conversion of preformed compound II to the native ferric
enzyme occurred with an isosbestic point at 442 nm (Fig. 2A).
During the slow conversion from compound II to the ferric enzyme,
the small maximum at 630 nm shifted to 625 nm which was
indicative of partial compound III formation [31]. Measurement of
the decrease in absorbance at 456 nm (Fig. 2B) gave an apparent
bimolecular rate constant of (9.8  0.6)  102 M1 s1 (pH 7.0,
25 8C) (Fig. 2C). The formation of some compound III, during the time
scale for reduction of compound II, most likely explains the negative
intercept observed in Fig. 2C because it also absorbs at 456 nm. These
rate constants indicate that INH is an effective substrate for
compound I but a relatively poor substrate for compound II.
3.2. Analysis of the oxidation products of INH
To better understand the mechanism by which MPO oxidizes
INH, we identified the products formed in the reaction and how
they are influenced by SOD. Methionine was included in reaction
mixtures to scavenge any HOCl formed by MPO when chloride was
present. Diethylenetriaminepentaacetic acid (DTPA) was also
included to chelate any metal cations that may otherwise catalyze
auto-oxidation of INH [5,32]. Incubation of INH with MPO (or
hydrogen peroxide alone, not shown) did not lead to oxidation
products observable above background by HPLC (Fig. 3A). Howev-
er, upon addition of MPO and hydrogen peroxide (Fig. 3B) three
products were formed. Two of them co-eluted with authentic
standards of isonicotinic acid (INA) or isonicotinamide (INAM)
(Fig. 3D). They also had the appropriate masses as determined by
mass spectrometry (result not shown). Isonicotinic acid was the
major oxidation product with reagent hydrogen peroxide. Addition
of SOD to MPO and INH promoted the formation of the same three
products without the requirement for exogenous hydrogen
Fig. 1. Reduction of MPO compound I by INH. Experiments were carried out in
sequential-mixing stopped-flow mode, pH 7.0, 25 8C. (A) Spectral changes upon
addition of 50 mM INH to 4 mM compound I. The first spectrum was recorded at
1.3 ms, subsequent spectra at 3.8, 6.4, 9.0, 11.5, 14.1, 19.2, 29.4, and 75 ms. Arrows
indicate absorbance changes. (B) A typical time trace of absorbance at 456 nm for
the reaction between 1 mM compound I and 25 mM INH. (C) Plot of the pseudo-first-
order rate constants of compound I reduction giving a second-order rate constant
(slope).
Fig. 2. Reduction of MPO compound II by INH. Experiments were carried out in
sequential-mixing stopped-flow mode, pH 7.0, 25 8C. (A) Spectral changes upon
addition of 5 mM INH to 4 mM compound II. The first spectrum was recorded at 1 s
(compound II), subsequent spectra were recorded at 1.6, 1.9, 2.2, 2.5 and 6.7 s. (B) A
typical time trace (456 nm) of the reaction between 1 mM compound II and 15 mM
INH. (C) Plot of the pseudo-first-order rate constants of compound II reduction
giving a second-order rate constant (slope).
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late eluting peak (approximately 16.5 min). SOD alone did not
oxidize INH (not shown). The photodiode array spectra observed
across the eluted peaks showed uniform profiles typical of the
pyridine chromophore with adsorption maxima at 262 nm (248–
267 nm range). The EP (and RSD PPI) values for peak purity, see
Section 2.3, were 1.30 (0.99%), 1.40 (0.13%), 1.45 (3.21%) and 3.63
(1.85%) for Fig. 3C peaks INA, INH, INAM and Met.A respectively.
These values indicate acceptable purity.The product with the longest retention time (approximately
16.5 min) had a m/z ratio of 255 and major fragments of 209 and
161 m/z (Fig. 3E). When the fragments with m/z values of 209 and
207 were subjected to further fragmentation (MS3), they both
gave rise to a molecular ion with a m/z value of 161. This
fragmentation pattern is consistent with the product being an
adduct between methionine and the isonicotinic acyl group of
INH (Fig. 3E inset). The adduct was not formed in the absence of
methionine (not shown). Related adducts were also formed
Fig. 3. Detection of INH oxidation products by HPLC and mass spectrometry. Typical
chromatograms (262 nm) of room temperature incubations of (A) 200 nM MPO and
200 mM INH in 10 mM phosphate buffer pH 7.4, 100 mM DTPA and 1 mM
methionine, (B) the same after 2 h with 100 mM H2O2 or (C) after 2 h with 40 mg/mL
SOD. (D) A mixture of standards containing 100 mM each of INH, isonicotinic acid
(INA) and isonicatinamide (INAM). (E) MS/MS analysis of the Met.A peak, with
proposed structures of fragmentation products (inset).
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the reaction instead of methionine (Table 1). No adduct was
formed with N-formyl methionine, nor with N-acetyl cysteine
(not shown). These results confirm that the amine group of these
amino acids is required for formation of the adducts. In each case
the product had a m/z ratio and fragments consistent with the
formation of an adduct between the amino acid and the
isonicotinic acyl group of INH (Table 1).When reagent hydrogen peroxide (25 mM) was added to MPO
(200 nM) and INH (200 mM), there was a slow oxidation of INH
that was complete within approximately 30 min (Fig. 4A). There
were corresponding increases in INA and the methionine adduct.
INAM remained a minor product. As the concentration of hydrogen
peroxide was increased in the reaction, there was an increase in the
extent of oxidation of INH to a maximum (Fig. 4B). At low
concentrations of hydrogen peroxide (10 mM) there was super-
stoichiometric oxidation of INH but at higher concentrations a
maximum of approximately 60 mM INH was oxidized. INA
accounted for 65–80% of the oxidized INH and INAM no more
than 5%. Assuming no other major products were produced, the
methionine adduct would have accounted for 15–30% of oxidized
INH. These data suggest that although hydrogen peroxide is
required for MPO to oxidize INH, at higher concentrations it must
also inhibit the reaction. Addition of SOD to MPO and INH
promoted a slow continuous linear oxidation of INH over 3 h even
though no exogenous hydrogen peroxide was added (Fig. 4C). INA
and INAM accounted for 49% and 6% of the oxidized INH, with the
remaining 45% attributed to the methionine adduct.
Chloride, the substrate for compound, I had no effect on
hydrogen peroxide dependent oxidation of INH. However, it
completely prevented oxidation of INH by MPO and SOD (Fig. 5A).
Catalase partially inhibited oxidation of INH by MPO and SOD
(Fig. 5B). This result demonstrated that hydrogen peroxide must be
produced during the oxidation of INH by MPO and SOD, and that it
is required to maintain further oxidation of INH.
3.3. Spectral analysis of MPO during oxidation of INH
The redox transformations of MPO were studied during
oxidation of INH using standard spectrophotometry to gain further
insights into the mechanisms of oxidation. Incubation of MPO with
INH alone displayed an unchanged native ferric MPO heme
spectrum with its Soret peak at 428 nm and a minor visible peak at
570 nm (Fig. 6A). Upon addition of hydrogen peroxide, MPO was
converted to compound II within 15 s as evident by the shift in the
Soret peak from 428 nm to 456 nm with the concomitant loss in
the peak at 570 nm and the appearance of a broad peak at 630 nm
[31]. By 10 min the compound II peak at 456 nm had declined with
a shoulder appearing at approximately 430 nm. There was also a
shift of the peak at longer wavelengths to a sharper peak at 625 nm.
These changes are indicative of conversion of the enzyme to a
mixture of native enzyme, compounds II and III [31]. In the
presence of physiological levels of chloride (Fig. 6B), there was a
smaller transformation away from the native ferric state to
compound II. This indicated that chloride was competing
effectively with INH and limiting its reaction with compound I.
To understand the pathway of conversion of compound II to
compound III when MPO oxidizes INH, preformed compound II
(gray trace) was reacted with INH (Fig. 6C). Addition of INH to
compound II resulted in a broadened Soret peak at 430 nm and a
pronounced peak at 625 nm. This spectrum formed within 1 min of
adding INH and was stable. It indicates the presence of ferric
enzyme and compound III. Without addition of INH, compound II
gradually reverted to the native ferric state with a minor amount
left after 7 min as evident from the small peak at 625 nm (dashed
black trace). From these results obtained over a time scale of
minutes, and the sub-second observations made in the stopped-
flow experiments (Fig. 2), we conclude that when compound II
reacts with INH it is initially reduced to ferric MPO, which is then
converted to compound III. The latter reaction does not involve INH
directly because in the absence of hydrogen peroxide, INH did not
affect the spectrum of native enzyme. Thus, an intermediate
formed during the oxidation of INH must react with the ferric
enzyme to form compound III.
Table 1
Formation of adducts between isoniazid and amine groups. Reaction mixtures of MPO (200 nM), isoniazid (200 mM) and SOD (20 mg/mL) were incubated at room temperature
in 10 mM phosphate buffer pH 7.4, containing 100 mM DTPA, for 3 h with or without an additional amino acid compound (1 mM) as listed. Isoniazid conjugate products were
detected (A262) by subjecting reaction mixtures to LCMS analysis. Subsequent identification of the adduct’s molecular structure was by MS/MS as described in Section 2. ND is
not detected.
Compound ([M+H]+ m/z) LCMS of isoniazid conjugate
Molecular structure RT (min) A262 [M+H]
+ m/z MS/MS fragments m/z
Isoniazid (alone) (138) 4.7 Yes
138
121.0
+ LMethionine (150) 17.4 Yes 255 207.2
209.0
211.2
161.1
+Methionine-DL-sulfoxide (166) 7.8, 9.3 Yes 271 207.2
+N-e-acetyl-L-lysine (189) 15.7 Yes 294 189.1
248.0
252.2
276.1
+N-formyl-L-methionine (178) – ND No – –
Bold type in MS/MS column denotes major fragments.
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superoxide or one-electron reduction of ferric enzyme to ferrous
MPO followed by rapid binding of oxygen [13]. To determine which
pathway was responsible for compound III formation during
oxidation of INH, we added SOD to the reaction system. Even in
the absence of hydrogen peroxide, MPO was converted almost
completely to compound III (Fig. 7A). This indicates that superoxide
was not responsible for forming compound III because SOD was
present and would scavenge this radical. Addition of catalase to
MPO, INH and SOD decreased the rate and extent of conversion of
MPO to compound III (Fig. 7B). This shows that hydrogen peroxide is
formed in this system and is required to promote conversion of the
enzyme to compound III. These data suggest that compound III is
formed by reduction of ferric MPO to ferrous MPO with subsequent
binding of oxygen, as occurs with substrates 4-amino benzoic acid
hydrazide (ABAH) [33], and hydroquinone [34].
3.4. The effect of INH on the halogenation activity of MPO
The production of HOCl by either a MPO-hydrogen peroxide
system or PMA-stimulated human neutrophils was measured by
trapping it with taurine and detecting accumulated taurine
chloramine [28]. INH was very effective at slowing the production
of HOCl by purified MPO (Fig. 8A). It inhibited the rate of its
production by 50% (IC50) at a concentration of 2.7 mM. The 1000-folddifference in rate constants for reduction of compounds I and II by
INH suggests that INH could inhibit MPO by promoting the
accumulation of compound II. However, inhibition of the production
of HOCl was only marginally affected by tyrosine (IC50 4.1 mM).
Tyrosine is a good substrate for compound II and prevents its
accumulation [35]. It has previously been shown to reverse
inhibition of hypochlorous acid production by inhibitors that trap
the enzyme in its compound II form [36,37]. Based on the modest
effect of tyrosine on inhibition of MPO by INH, we conclude that INH
is unlikely to act solely by converting the enzyme to compound II.
INH was also a good inhibitor of HOCl production by neutrophils
having an IC50 of 7.5 mM (Fig. 8B). SOD, added to remove superoxide,
marginally improved the potency of inhibition (IC50 3.7 mM). INH
(20 mM) did not affect production of superoxide by neutrophils nor
did it prevent HOCl from reacting with taurine. Similarly, neither
isonicotinic acid nor isonicotinamide inhibited MPO in the taurine
chloramine assay at a concentration of 20 mM (results not shown).
Consequently, we conclude that INH must inhibit production of
hypochlorous acid by interacting directly with MPO.
3.5. Reversibility of MPO inhibition by INH
Previously, it was demonstrated that ABAH, a structural analog
of INH, irreversibly inactivates MPO by destroying the heme
prosthetic groups of the enzyme [33,38]. Therefore we investigated
Fig. 4. Oxidation of INH by MPO in the presence of H2O2 or SOD. The loss of INH (~)
and formation of oxidation products (INA *, INAM *, Met.A &) was monitored
upon incubation of 200 nM MPO, 200 mM INH in 10 mM phosphate buffer pH 7.4
containing 100 mM DTPA and 1 mM methionine, with (A) 25 mM H2O2, (B) with
varied H2O2 concentration for 1 h, and (C) with 40 mg/mL SOD. All data shown are
the means from two to four experiments, error bars are standard deviations (SD).
Fig. 5. The effect of chloride on isoniazid oxidation, and moderation of the SOD effect
by catalase. (A) 200 nM MPO was incubated with 200 mM INH for 1 h at room
temperature in 10 mM phosphate buffer pH 7.4 containing 100 mM DTPA, 1 mM
methionine, 140 mM NaCl, with either 100 mM H2O2 or 40 mg/mL SOD. Reaction
mixtures were analyzed by HPLC for INH (black bar), INA (light gray), INAM (dark gray)
and Met.A (striped). Data presented are the means and ranges of duplicate experiments,
and are representative of three experiments. (B) 200 nM MPO and 200 mM INH were
incubated in 10 mM phosphate buffer pH 7.4 containing 100 mM DTPA for 5 h, with or
without catalase (20 mg/mL) and SOD (40 mg/mL). Results shown are the means and
ranges from two experiments, both carried out in the absence of methionine.
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incubated with hydrogen peroxide in the absence or presence of
INH. It was then diluted 200-fold, to effectively remove any
ambient inhibitor, and the residual peroxidase activity was
measured. Incubation of MPO with hydrogen peroxide alone
caused a decrease in the activity of MPO (Fig. 9A). The presence of
INH, however, had no additional effect on the residual activity of
MPO. In contrast, but consistent with previous results [33], ABAH
caused a 90% loss in enzyme activity.
The effect of INH on the specific activity of MPO was also
measured using an activity ELISA. After incubating MPO with INHand hydrogen peroxide, MPO was captured on an ELISA plate and
its activity as well as the amount of MPO was measured. The ratio
of these two measurements was used to calculate the specific
activity of MPO. INH had a modest effect on the specific activity of
MPO with the greatest effect occurring at higher concentrations of
hydrogen peroxide. At most there was only approximately 30% loss
in specific activity (Fig. 9B). This was unaffected by the presence or
absence of chloride in the incubation (not shown). Under the same
conditions, however, ABAH completely inactivated MPO. These
results show that there is some irreversible component to MPO
inhibition by INH but this occurs only at high concentrations of
hydrogen peroxide. Thus, the predominant mechanism is not that
of an irreversible mechanism-based inhibitor.
4. Discussion
It is becoming increasingly apparent that neutrophils play a
major role in host defense against Mtb [39]. This view is confirmed
by the recent finding that neutrophils are the predominant
infected phagocytic cell in the airways of patients with active
pulmonary tuberculosis [6]. Elevated levels of MPO in pleural fluid
[40] and serum of infected individuals [41] demonstrates that this
Fig. 6. Spectral changes of MPO during oxidation of INH. (A) Native ferric MPO
(1.2 mM) was incubated with INH (10 mM) in 100 mM phosphate buffer pH 7.4
containing 1 mM methionine (gray line). H2O2 (40 mM) was added and spectra were
recorded after 15 s (dashed black line), and after 10 min (solid black line). (B) The
same as (A) but with 140 mM NaCl in the buffer. (C) MPO (1 mM) was converted to
compound II (gray line) by adding H2O2 (167 mM) to the enzyme in 50 mM
phosphate buffer pH 7.4 containing 1 mM methionine. Catalase (20 mg/mL) was
then added to remove excess H2O2 and the spectrum was recorded 7 min later
(dashed black line). This is compared to the same system with INH (200 mM) added
after the catalase, the spectrum recorded 1 min later (solid black line).
Fig. 7. Spectral changes of MPO in the presence of INH and SOD. MPO (0.8 mM) was
incubated in 50 mM phosphate buffer pH 7.4 containing 1 mM methionine, in the
absence (A) or presence (B) of 20 mg/mL catalase. After an initial spectrum was
recorded (gray line), INH (200 mM) and SOD (40 mg/mL) were added and spectra
were recorded 1 min later (dashed black line). By 4 min stable spectra were
recorded that remained unchanged up to 30 min later (solid black line).
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pharmacology of tuberculosis. Consequently, our new data on
interactions between INH and MPO are pertinent to the effective
treatment of patients with tuberculosis. We have shown that thereaction of INH with compound I of MPO is fast enough to ensure
that it could occur at the sites of infection and inflammation.
Oxidation of the drug by the enzyme is plausible because chloride,
the physiological major substrate for MPO, had little influence on
the hydrogen peroxide-dependent metabolism of INH. Our
findings also demonstrate that once oxidized by MPO, INH will
become conjugated to amine groups on proteins. These conjugates
are potential haptens that may explain the autoimmune complica-
tions associated with extended treatment with INH. It is also
apparent that interactions with INH will limit the ability of MPO to
produce HOCl, which may compromise host defense against Mtb.
To fully appreciate how the interactions of INH and MPO will
manifest in vivo, it is necessary to understand the mechanisms by
which MPO oxidizes INH and the ultimate fate of the reactive
species that are formed. The proposed mechanisms of oxidation of
INH are outlined in Schemes 1 and 2.
We found that INH was a good substrate for compound I but
reacted more slowly with compound II. The rate constant for
reaction of compound I with INH has a similar value to those for
physiological organic substrates such as urate, tyrosine, and
ascorbate [15,19,35]. The reaction is also sufficiently fast to
compete with oxidation of chloride [42] (see Scheme 1). The much
larger rate constant for MPO compared to that for compound I of
KatG (4.3  104 M1 s1) most likely reflects the high reduction
potential of the mammalian enzyme [16]. INH was a poor substrate
Fig. 8. Effect of INH on production of HOCl by purified MPO and isolated neutrophils.
(A) MPO (20 nM) was incubated at room temperature with various concentrations
of INH in PBS containing 5 mM taurine. Reactions were started by adding 50 mM
H2O2 and stopped after 5 min with 20 mg/mL catalase, and were either in the
presence (open circles) or absence (filled circles) of 10 mM tyrosine. Data are
means  SD representative of three experiments. (B) Neutrophils (2  106/mL) were
stimulated with PMA (100 ng/mL) in Hanks buffer pH 7.4, containing 5 mM taurine and
various concentrations of INH. Reactions were performed at 37 8C in the presence
(open circles) or absence (filled circles) of 40 mg/mL SOD and stopped after 20 min.
Cells (SOD) produced 22  1 mM HOCl. Inhibition of HOCl production was
determined relative to the control level measured in the absence of inhibitor. Data
are means  SEM of duplicates, and are representative of three experiments.
Fig. 9. Analysis of the reversibility of inhibition of MPO by INH. (A) MPO (150 nM)
was incubated at room temperature in 10 mM phosphate buffer pH 7.4, containing
100 mM DTPA, in the absence or presence of INH (50 mM) or ABAH (50 mM) as well
as without (black bars) or with (gray bars) H2O2 (50 mM). Residual MPO activity was
determined after 30 min and is relative to the control activity of MPO incubated
without H2O2 or inhibitor. Mean values are plotted with SD error bars. (B) MPO
(100 nM) was incubated at room temperature in 100 mM phosphate buffer pH 7.4,
containing 140 mM NaCl, 1 mM methionine, 100 mM DTPA, INH (1 mM) or ABAH
(1 mM), with increasing concentrations of H2O2. Catalase (20 mg/mL) was added after
15 min, then the specific activity was determined by ELISA. Specific activity is reported
as the ratio of activity to the amount of protein, relative to that measured for MPO
incubated without H2O2 or inhibitor. Data are means of duplicates  the sum of SD for
the protein and activity measurements, and representative of two experiments.
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physiological substrates for this redox intermediate. It is not
immediately apparent why the reaction is slow because INH is a
similar size to urate, ascorbate, and tyrosine, while the 1-electron
oxidation to generate its radical (reduction potential of 500 mV)
is similar to that of urate (590 mV) and much less than that of
tyrosine (980 mV) [43,44]. Hence, it would be expected to react at
comparable rates to these substrates. With salicylhydroxamic acid,
which is structurally related to INH, the aromatic ring binds to a
hydrophobic region at the entrance to the distal heme pocket of
MPO, while the hydroxamic acid moiety is hydrogen bonded to
both the distal histidine 95 and the adjacent glutamine 91 amide
group above the heme iron [45]. This orientation would be
expected to favor oxidation. However, INH may react slowly
because the orientation of the hydrazide moiety within the active
site could be away from the heme group as occurs in lactoper-
oxidase [46]. The constrained active site of compound II may alsorestrict access of the hydrazide moiety [47]. Although compara-
tively slow, this reaction is much faster than the analogous
reaction with compound II of HRP (40 M1 s1) [48].
Based on the measured rate constants, MPO will at least initially
oxidize INH to the hydrazyl radical (RH in Schemes 1 and 2 in
Scheme 2) via the classical peroxidation cycle (Scheme 1).
However, in the stopped-flow experiments and steady-state
spectral studies, it was apparent that compound II is eventually
converted to compound III in a reaction that is independent of
superoxide. Others have reported conversion of MPO and HRP to
compound III during oxidation of INH [48–50]. Also, an analogous
reaction occurs when MPO oxidizes ABAH, hydroquinone and
melatonin [33,34,51]. We found that INH did not directly reduce
ferric MPO and propose that the hydrazyl radical reduces the ferric
enzyme because it is formed upon oxidation by compounds I and II.
This reaction would produce ferrous MPO (Scheme 1) and implies
that the hydrazyl radical is strongly reducing because the
Scheme 1. Mechanism of oxidation of INH by MPO. The reaction scheme shows the
redox transformations of MPO during the oxidation of isoniazid. The different redox
cycles include (a) chlorination, (b) classical peroxidation, (c) peroxidation involving
ferrous MPO, and (d) peroxidation involving ferrous MPO and compound III. RH2 is
isoniazid, RH is the hydrazyl radical, and R is the acyl diimide. For simplicity, only
major products are shown.
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278 mV, respectively. A similar reaction may occur with KatG
because reported values for the reduction potential [44,52,53] sit
between those for these peroxidases.
Once formed, ferrous MPO binds molecular oxygen in an
equilibrium reaction to form compound III [17,18] or reacts with
hydrogen peroxide to produce compound II [54]. Compound III
would be formed at low concentrations of hydrogen peroxide, as
observed in the SOD system. Compound III must turnover to
sustain the oxidation of INH. In our reaction system, turnover
would occur via reduction of compound III by INH to form
compound I (Scheme 1). In support of this proposal, it has
previously been shown that compound III is reduced by ascorbate
[19], superoxide [20], and serotonin [21]. Compound III or
oxyperoxidase of KatG is also reduced by INH [55]. The cycle
with compound III would be fueled by molecular oxygen and
produce super-stoichiometric concentrations of oxidized INH as
observed with either SOD or addition of low concentrations of
hydrogen peroxide. The cycle would be interrupted by chloride
reacting with compound I, which would inhibit oxidation of INH as
observed in the SOD system. At higher concentrations of hydrogen
peroxide, ferrous MPO would be converted to compound II. Under
these conditions a catalytic cycle involving ferric MPO, ferrous
MPO as well as compounds I and II would be responsible for
oxidizing INH (Scheme 1). The inability of hydrogen peroxide at
higher concentrations to promote further oxidation of INH is
explained by its capacity to inactivate the enzyme (see Fig. 9A) and
react with compound I [56,57]. In addition to these mechanisms,
good substrates for compounds I and II that produce oxidizing
radicals, such as tyrosine, may also promote the oxidation of INH to
the hydrazyl radical [48]. Thus, at sites of infection with Mtb, MPO
is a credible candidate for the metabolism of INH and formation of
hydrazyl radicals.
The fate of the hydrazyl radicals (2) is shown in Scheme 2 and
will depend primarily on the local concentration of ascorbate and
superoxide dismutase. Based on its reduction potential ofapproximately 0.5 V [44], the hydrazyl radical would be readily
reduced by ascorbate (E80 Asc/Asc 0.28 V) [43]. However, at low
concentrations of ascorbate, as will occur at sites of inflammation
where there is considerable oxidative stress, it will be free to react.
It could break down to the acyl radical (4), or form the acyldiimide
(3) either by disproportionation or reaction with molecular oxygen
[58,59]. The acyl radical will react at diffusion controlled rates with
oxygen to produce a peroxyl radical (5), which may foster a chain
reaction by oxidizing another INH molecule and forming an
acylhydroperoxide (6). Spin trapping experiments have previously
established the existence of these radical species during peroxi-
dase-mediated oxidation of INH [8]. The peroxyl radicals are highly
oxidizing and in vivo they would promote free radical chain
reactions such as lipid peroxidation.
Our finding that SOD promoted MPO-dependent oxidation of
INH in the absence of added hydrogen peroxide illuminates the
fate of the hydrazyl radicals. The effect of SOD is reminiscent of
how it boosted the rate and stoichiometry of hydroquinone
oxidation by MPO [34]. This was explained by the ability of SOD to
shift the equilibrium for reduction of molecular oxygen by the
semiquinone to the right simply by preventing the reverse
reaction. In line with this chemistry, we propose that low
concentrations of endogenous hydrogen peroxide present in the
buffer are sufficient to initiate oxidation of INH by MPO to give the
hydrazyl radical (2). It would not normally react with molecular
oxygen because the equilibrium for this reaction would be strongly
favored to the left as occurs with the analogous reactions of
quinones with superoxide. In the presence of SOD, however, the
equilibrium will be shifted to the right so that the acyl diimide (3)
and hydrogen peroxide are produced. As long as molecular oxygen
is available, the hydrogen peroxide formed by SOD would promote
further oxidation of INH (Scheme 2).
We found that SOD also increased the proportion of oxidized
INH that was conjugated to methionine. This is consistent with our
mechanism if the resultant acyl diimide (3) undergoes nucleophilic
attack by amines to form adducts (8). In support of this proposal,
the acyl diimide of INH has been shown to undergo facile
nucleophilic substitution reactions [60]. In the absence of SOD
some of the hydrazyl radical must disproportionate to the acyl
diimide (3) and form the adducts with methionine (8) as well as
INA (7). In the presence of SOD, less of the hydrazyl radical (2)
would breakdown to the acyl radical (4) while more would be
converted to the acyl diimide (3). Consequently, the relative
proportion of the methionine adduct (8) to INA (7) would increase
because the route leading to INA via the acyl radical (5) would be
attenuated by SOD while that for the adduct would be enhanced.
The effect of SOD has important consequence for oxidation of
INH in vivo. Mtb actively secretes an iron-containing superoxide
dismutase (SODA) to inhibit the host responses to infections
[11,12]. Hence sites of infection populated by neutrophils and Mtb
will contain both MPO and SODA. Under these circumstances SODA
will shift the hydrazyl radical formed by MPO toward the
acyldiimide and subsequent conjugation to proteins. This is likely
to spark the immune reactions of INH-induced lupus that have
already been suspected to involve neutrophils and MPO. The
potential for the radical intermediates of INH and the acylhy-
droperoxide to cause toxicity to host cells as well as Mtb also
warrants consideration.
One of the new findings of our study is that INH is a good
inhibitor of the chlorination activity of MPO and production of
HOCl by neutrophils. The mechanism of inhibition involves
competition between chloride and INH for oxidation by
compound I with subsequent diversion of the enzyme along
pathways involving compound II, ferrous MPO, and compound III
that are outside the normal chlorination cycle (Scheme 1).
Inhibition is not explained simply by the slow turnover of
Scheme 2. Pathways for oxidation of INH by MPO. The different structures are (1) isoniazid, (2) hydrazyl radical, (3) acyl diimide, (4) acyl radical, (5) acyl peroxyl radical, (6)
acyl hydroperoxide, (7) isonicotinic acid and (8) an acyl adduct with an amino acid. RNH2 is ammonia or an amino acid.
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reduce this intermediate, could not effectively mitigate the loss
in activity. The mechanism differs from those for ABAH [33] and
2-thioxanthines [61] because we found no evidence for
irreversible enzyme inactivation. Inhibition occurred at con-
centrations well below the therapeutic dose so INH can be
expected to inhibit production of HOCl at sites of Mtb infection. It
should certainly inhibit production of HOCl by extracellular
MPO. Whether or not it inhibits MPO within phagosomes and
compromises host defense will depend on how readily it enters
and accumulates within these compartments.
In summary, we have delineated the interactions between INH
and MPO that will influence both the efficacy and adverse effects of
this important drug. Exactly how these interactions manifest at
sites of infection and whether they could be controlled will require
further investigation. Demonstrating the conjugation of the acyl
diimide to lysine residues in airway proteins from patients treated
with INH will be a first step in this inquiry. Such data would
provide the rationale for using ascorbate to scavenge INH radicals
in an attempt to attenuate the adverse effects of INH.Acknowledgments
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